RxDoctor Payments Data

Paul Ryan, MD

Interventional Cardiology · Hinsdale, ILNPI 1497750749

Payments from drug & device makers

$1,043in general payments, 2019–2025

Across 35 payments — averaging $29.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$265
  • Boston Scientific$257
  • Boehringer Ingelheim$121
  • Shockwave Medical, Inc$119
  • Edwards Lifesciences$103
  • Philips North America LLC$72
  • plus $105 from 4 others

What the payments were for

  • Food & beverage$1,043100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,043 in reported general payments places this provider in the 10th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$221,762
Medicare patients
1,272
Services billed
3,445

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban309$305,492
XareltoRivaroxaban52$57,228
EntrestoSacubitril/Valsartan18$14,221
JardianceEmpagliflozin22$12,936
BrilintaTicagrelor13$6,485
Metoprolol Succinate319$6,136
Atorvastatin Calcium479$5,284
Metoprolol Tartrate254$2,349
Rosuvastatin Calcium161$2,324
ClopidogrelClopidogrel Bisulfate182$2,098
VascepaIcosapent Ethyl12$2,084
Warfarin Sodium120$2,064
Amlodipine Besylate268$1,994
Lisinopril149$1,415
Losartan Potassium152$1,412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$26$57,22852 claims
NovartisEntresto$38$14,22118 claims
Boehringer IngelheimJardiance$121$12,93622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Hinsdale

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →